



All Wales Therapeutics
and Toxicology Centre

Canolfan Therapiwteg a
Thocsicoleg Cymru Gyfan


AWMSG SECRETARIAT ASSESSMENT REPORT

Travoprost (Travatan®)

40 micrograms/ml eye drops, solution

Reference number: 2601

LIMITED SUBMISSION



This report has been prepared by the All Wales Therapeutics and Toxicology Centre (AWTTC), in collaboration with the Centre for Health Economics & Medicines Evaluation, Bangor University.

Please direct any queries to AWTTC:

All Wales Therapeutics and Toxicology Centre (AWTTC)
University Hospital Llandough
Penlan Road
Llandough
Vale of Glamorgan
CF64 2XX

awttc@wales.nhs.uk

029 2071 6900

This report should be cited as:
All Wales Therapeutics and Toxicology Centre. AWMSG Secretariat Assessment Report. Travoprost (Travatan®) 40 micrograms/ml eye drops, solution. Reference number: 2601. September 2015.

AWMSG Secretariat Assessment Report – Limited submission

Travoprost (Travatan[®]) 40 micrograms/ml eye drops, solution

Company: Alcon Laboratories (UK) Ltd

Date of submission: 19 June 2015

Licensed indication under consideration:

Decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma.

Refer to the Summary of Product Characteristics (SPC) for the full licensed indication.

Marketing authorisation date: 19 December 2014

Comparator(s)

- Timolol – off label use
- Latanoprost – only licensed comparator

Limited submission details

- Minor licence extension

Clinical effectiveness

- A phase III study (C-12-008) showed travoprost 0.004% ophthalmic solution once daily was non-inferior to timolol (0.5%) twice daily. The Committee for Medicinal Products for Human Use (CHMP) concluded that a comparative study of travoprost and timolol is acceptable.
- In the absence of head-to-head trials of latanoprost versus travoprost, an indirect treatment comparison (ITC) was provided. A small numerical difference in the reduction of intraocular pressure between latanoprost and travoprost was observed ($p > 0.1$). Results should be treated with caution due to the inherent limitations associated with ITCs.
- CHMP conclude that the safety profile of travoprost in the paediatric population is consistent with that seen in the adult population.

Budget impact

- The company estimate that there are 6,660 children with glaucoma in Wales.
- Based on 2015 Prescription Cost Analysis (PCA) data, the company state that latanoprost is the most highly prescribed prostaglandin analogue for the overall treatment of glaucoma in Wales, with travoprost accounting for 14.6% of prescriptions.
- Since only latanoprost is currently licensed for use in the paediatric population, the company have assumed that the market share of Xalatan[®] is 5.5%, with the remaining 94.5% being non-proprietary latanoprost for both adult and paediatric

use (with any travoprost prescriptions being for adult use only).

- The current cost to NHS Wales for the treatment of paediatric patients with ocular hypertension or paediatric glaucoma, based on the patient numbers and anticipated market share provided by the company, is £82,712 per annum.
- The company have assumed a modest gradual uptake of travoprost, with displacement of both Xalatan[®] and non-proprietary latanoprost, proportional to their current usage. The company therefore estimate a budget impact of £12,498 in Year 1 rising to £32,494 by Year 5.
- The budget impact is subject to some uncertainty and would be dependent on whether travoprost displaced non-proprietary latanoprost, Xalatan[®], or a proportion of both.

Additional information

- AWTTTC is of the opinion that, if recommended, travoprost (Travatan[®]) is appropriate for specialist only prescribing within NHS Wales for the indication under consideration.

Evidence search

Date of evidence search: 4 June 2015

Date of range of evidence search: No date limits were applied to database searches.

AWMSG review

This assessment report will be considered for review every three years.

References are available on request. Please email AWTTTC at AWTTTC@Wales.nhs.uk for further information.